ChartRow logo
Data provided bySource: Twelve Data
ROIV
$38.71+0.26%
as of close, Nov 17, 2026
☾ AH $38.71 +0.26%
Share this page

ROIV SEC filings (2026)

CIK 1635088 · Pharmaceutical Preparations (SIC 2834) · incorporated in D0 · fiscal year ends in March

1,015 filings on EDGAR since 2015 · 5 annual, 17 quarterly, 83 current · financial statements · earnings

Latest 10-K
May 20, 2026
fiscal year to Mar 31, 2026
Latest 10-Q
Nov 9, 2026
quarter to Sep 30, 2026
Latest 8-K
Nov 9, 2026
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
Last earnings release
Nov 9, 2026
−$0.30 vs −$0.52 · ▲ 4.6%
Filings on file
1,015
since 2015, 708 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

November 2026

October 2026

September 2026

August 2026

July 2026

June 2026

May 2026

April 2026

March 2026

February 2026

January 2026

December 2025

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $526.6M in 55 sales and bought nothing on the open market; 138 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

DateInsider
Nov 11, 2026Form 4Pulik RichardCFOSold · $7.3M · 175,000 sh
Nov 10, 2026Form 4Venker EricPresident & Immunovant CEOSold · $7.6M · 187,943 sh · 10b5-1
Nov 10, 2026Form 4Pulik RichardCFOSold · $5.2M · 125,000 sh
Nov 3, 2026Form 4Venker EricPresident & Immunovant CEOSold · $7.3M · 200,000 sh · 10b5-1
Oct 28, 2026Form 4Venker EricPresident & Immunovant CEOSold · $7.3M · 200,000 sh · 10b5-1
Oct 20, 2026Form 4Venker EricPresident & Immunovant CEOSold · $7.0M · 200,000 sh · 10b5-1
Oct 1, 2026Form 4Epperly Melissa B,DirectorSold · $641K · 17,750 sh · 10b5-1
Sep 30, 2026Form 4Venker EricPresident & Immunovant CEOSold · $7.3M · 200,000 sh · 10b5-1
Sep 15, 2026Form 4Fitzgerald MeghanDirectorSold · $203K · 5,112 sh · 10b5-1
Sep 15, 2026Form 4Epperly Melissa B,DirectorSold · $196K · 4,938 sh · 10b5-1
Sep 8, 2026Form 4Fitzgerald MeghanDirectorSold · $798K · 20,000 sh · 10b5-1
Aug 28, 2026Form 4Venker EricPresident & Immunovant CEOSold · $7.2M · 200,000 sh · 10b5-1
Aug 21, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorSold · $5.3M · 144,756 sh
Aug 20, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorSold · $653K · 17,519 sh
Aug 19, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorSold · $6.4M · 172,899 sh
Aug 18, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorSold · $5.0M · 136,942 sh
Aug 17, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorSold · $10.3M · 284,707 sh
Aug 14, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorSold · $8.8M · 243,177 sh
Jul 27, 2026Form 4Venker EricPresident & Immunovant CEOSold · $7.0M · 200,000 sh · 10b5-1
Jun 30, 2026Form 4MANCHESTER KEITH SDirectorSold · $7.5M · 212,380 sh
Jun 30, 2026Form 4QVT Financial LPDirector by DeputizationSold · $437K · 12,380 sh
Jun 30, 2026Form 4Gold Daniel AllenDirectorSold · $437K · 12,380 sh
Jun 30, 2026Form 4Fitzgerald MeghanDirectorSold · $349K · 10,000 sh · 10b5-1
Jun 29, 2026Form 4QVT Financial LPDirector by DeputizationSold · $27.6M · 800,000 sh
Jun 29, 2026Form 4Gold Daniel AllenDirectorSold · $27.6M · 800,000 sh
Jun 29, 2026Form 4MANCHESTER KEITH SDirectorSold · $27.6M · 800,000 sh
Jun 29, 2026Form 4Epperly Melissa B,DirectorSold · $610K · 17,750 sh · 10b5-1
Jun 26, 2026Form 4QVT Financial LPDirector by DeputizationSold · $21.3M · 625,783 sh
Jun 26, 2026Form 4Gold Daniel AllenDirectorSold · $21.3M · 625,783 sh
Jun 26, 2026Form 4MANCHESTER KEITH SDirectorSold · $21.3M · 625,783 sh
Jun 26, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorSold · $17.0M · 500,000 sh
Jun 25, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorSold · $17.1M · 500,000 sh
Jun 24, 2026Form 4Venker EricPresident & Immunovant CEOSold · $6.6M · 200,000 sh · 10b5-1
May 22, 2026Form 4Venker EricPresident & Immunovant CEOSold · $6.1M · 200,000 sh · 10b5-1
Apr 20, 2026Form 4Venker EricPresident & Immunovant CEOSold · $5.9M · 200,000 sh · 10b5-1
Apr 16, 2026Form 4Gline MatthewCEO · DirectorSold · $8.4M · 289,774 sh
Apr 8, 2026Form 4Humes JenniferChief Accounting OfficerSold · $384K · 13,538 sh
Mar 26, 2026Form 4Fitzgerald MeghanDirectorSold · $1.9M · 70,000 sh
Mar 17, 2026Form 4Venker EricPresident & Immunovant CEOSold · $5.6M · 200,000 sh · 10b5-1
Mar 16, 2026Form 4Epperly Melissa B,DirectorSold · $1.2M · 41,861 sh
Feb 23, 2026Form 4Torti FrankPresident and Vant ChairSold · $16.2M · 587,390 sh · 10b5-1
Feb 20, 2026Form 4Torti FrankPresident and Vant ChairSold · $27.5M · 1,012,610 sh · 10b5-1
Feb 19, 2026Form 4Torti FrankPresident and Vant ChairSold · $38.4M · 1,400,000 sh · 10b5-1
Feb 13, 2026Form 4QVT Financial LPDirector by DeputizationSold · $10.0M · 375,784 sh
Feb 13, 2026Form 4Gold Daniel AllenDirectorSold · $10.0M · 375,784 sh
Feb 13, 2026Form 4MANCHESTER KEITH SDirectorSold · $10.0M · 375,784 sh
Feb 13, 2026Form 4Venker EricPresident & Immunovant CEOSold · $5.3M · 200,000 sh · 10b5-1
Feb 12, 2026Form 4QVT Financial LPDirector by DeputizationSold · $11.4M · 425,000 sh
Feb 12, 2026Form 4Gold Daniel AllenDirectorSold · $11.4M · 425,000 sh
Feb 12, 2026Form 4MANCHESTER KEITH SDirectorSold · $11.4M · 425,000 sh
Feb 11, 2026Form 4QVT Financial LPDirector by DeputizationSold · $11.3M · 425,000 sh
Feb 11, 2026Form 4Gold Daniel AllenDirectorSold · $11.3M · 425,000 sh
Feb 11, 2026Form 4MANCHESTER KEITH SDirectorSold · $11.3M · 425,000 sh
Feb 9, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorSold · $9.0M · 339,441 sh
Jan 12, 2026Form 4Venker EricPresident & Immunovant CEOSold · $4.4M · 200,000 sh · 10b5-1
Awards, exercises, withholding and plan purchases · 138 transactions
DateInsider
Nov 12, 2026Form 4Torti FrankPresident and Vant ChairOther · $15.9M · 392,043 sh
Nov 12, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorOther · $2.2M · 53,205 sh
Nov 12, 2026Form 4Gline MatthewCEO · DirectorOther · $2.0M · 48,988 sh
Nov 12, 2026Form 4Torti FrankPresident and Vant ChairTax withholding · $536K · 12,800 sh
Nov 12, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorTax withholding · $73K · 1,737 sh
Nov 12, 2026Form 4Gline MatthewCEO · DirectorTax withholding · $67K · 1,600 sh
Nov 11, 2026Form 4Torti FrankPresident and Vant ChairOther · $16.4M · 392,048 sh
Nov 11, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorOther · $2.2M · 53,205 sh
Nov 11, 2026Form 4Gline MatthewCEO · DirectorOther · $2.0M · 48,988 sh
Nov 11, 2026Form 4Pulik RichardCFOExercise or conversion · $490K · 127,365 sh
Nov 11, 2026Form 4Pulik RichardCFOExercise or conversion · Stock Option (Right to Buy) · $0 · 127,365 sh
Nov 10, 2026Form 4Torti FrankPresident and Vant ChairOther · $16.0M · 392,052 sh
Nov 10, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorOther · $2.4M · 59,034 sh
Nov 10, 2026Form 4Gline MatthewCEO · DirectorOther · $2.4M · 58,331 sh
Nov 10, 2026Form 4Pulik RichardCFOExercise or conversion · $481K · 125,000 sh
Nov 10, 2026Form 4Pulik RichardCFOExercise or conversion · Stock Option (Right to Buy) · $0 · 125,000 sh
Oct 23, 2026Form 4Epperly Melissa B,DirectorTax withholding · $4,233 · 116 sh
Oct 23, 2026Form 4MOMTAZEE JAMES CDirectorTax withholding · $2,810 · 77 sh
Oct 23, 2026Form 4Oren IlanDirectorAward · $0 · 810 sh
Oct 23, 2026Form 4Epperly Melissa B,DirectorAward · $0 · 513 sh
Oct 23, 2026Form 4MOMTAZEE JAMES CDirectorAward · $0 · 383 sh
Oct 16, 2026Form 4Gline MatthewCEO · DirectorTax withholding · $1.2M · 34,638 sh
Oct 16, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorTax withholding · $670K · 19,976 sh
Oct 1, 2026Form 4Epperly Melissa B,DirectorExercise or conversion · $79K · 17,750 sh · 10b5-1
Oct 1, 2026Form 4Epperly Melissa B,DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 17,750 sh · 10b5-1
Sep 30, 2026Form 4Gline MatthewCEO · DirectorTax withholding · $2.8M · 76,171 sh
Sep 30, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorTax withholding · $1.7M · 46,879 sh
Sep 30, 2026Form 4Torti FrankPresident and Vant ChairTax withholding · $1.5M · 40,309 sh
Sep 30, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1
Sep 30, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1
Sep 20, 2026Form 4Humes JenniferChief Accounting OfficerTax withholding · $154K · 3,880 sh
Sep 20, 2026Form 4Pulik RichardCFOTax withholding · $85K · 2,129 sh
Sep 16, 2026Form 4MANCHESTER KEITH SDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh
Sep 16, 2026Form 4MOMTAZEE JAMES CDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh
Sep 16, 2026Form 4Fitzgerald MeghanDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh
Sep 16, 2026Form 4Oren IlanDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh
Sep 16, 2026Form 4Gold Daniel AllenDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh
Sep 16, 2026Form 4Epperly Melissa B,DirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh
Sep 16, 2026Form 4MANCHESTER KEITH SDirectorAward · $0 · 5,054 sh
Sep 16, 2026Form 4MOMTAZEE JAMES CDirectorAward · $0 · 5,054 sh
Sep 16, 2026Form 4Fitzgerald MeghanDirectorAward · $0 · 5,054 sh
Sep 16, 2026Form 4Oren IlanDirectorAward · $0 · 5,054 sh
Sep 16, 2026Form 4Gold Daniel AllenDirectorAward · $0 · 5,054 sh
Sep 16, 2026Form 4Epperly Melissa B,DirectorAward · $0 · 5,054 sh
Sep 10, 2026Form 4Gold Daniel AllenDirectorTax withholding · $210K · 5,133 sh
Sep 10, 2026Form 4MOMTAZEE JAMES CDirectorTax withholding · $119K · 2,905 sh
Sep 10, 2026Form 4Oren IlanDirectorTax withholding · $97K · 2,378 sh
Sep 10, 2026Form 4Epperly Melissa B,DirectorTax withholding · $89K · 2,179 sh
Sep 10, 2026Form 4Fitzgerald MeghanDirectorTax withholding · $71K · 1,743 sh
Sep 8, 2026Form 4Fitzgerald MeghanDirectorExercise or conversion · $176K · 20,000 sh · 10b5-1
Sep 8, 2026Form 4Fitzgerald MeghanDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 20,000 sh · 10b5-1
Aug 28, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1
Aug 28, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1
Aug 21, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $557K · 144,756 sh
Aug 21, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 144,756 sh
Aug 20, 2026Form 4Venker EricPresident & Immunovant CEOTax withholding · $512K · 13,909 sh
Aug 20, 2026Form 4Pulik RichardCFOTax withholding · $212K · 5,749 sh
Aug 20, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $67K · 17,519 sh
Aug 20, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 17,519 sh
Aug 19, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $666K · 172,899 sh
Aug 19, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 172,899 sh
Aug 18, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $527K · 136,942 sh
Aug 18, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $0 · 136,942 sh
Aug 17, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $1.1M · 284,707 sh
Aug 17, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $0 · 284,707 sh
Aug 14, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $936K · 243,177 sh
Aug 14, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $0 · 243,177 sh
Jul 27, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1
Jul 27, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1
Jul 17, 2026Form 4Oren IlanDirectorAward · $0 · 775 sh
Jul 17, 2026Form 4Epperly Melissa B,DirectorAward · $0 · 543 sh
Jul 17, 2026Form 4MOMTAZEE JAMES CDirectorAward · $0 · 405 sh
Jun 30, 2026Form 4Gline MatthewCEO · DirectorTax withholding · $2.7M · 76,171 sh
Jun 30, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorTax withholding · $1.7M · 46,878 sh
Jun 30, 2026Form 4Torti FrankPresident and Vant ChairTax withholding · $1.4M · 40,310 sh
Jun 30, 2026Form 4Fitzgerald MeghanDirectorExercise or conversion · $88K · 10,000 sh · 10b5-1
Jun 30, 2026Form 4Fitzgerald MeghanDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 10,000 sh · 10b5-1
Jun 29, 2026Form 4Epperly Melissa B,DirectorExercise or conversion · $79K · 17,750 sh · 10b5-1
Jun 29, 2026Form 4Epperly Melissa B,DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 17,750 sh · 10b5-1
Jun 26, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $1.9M · 500,000 sh
Jun 26, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 500,000 sh
Jun 25, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $1.9M · 500,000 sh
Jun 25, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 500,000 sh
Jun 24, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1
Jun 24, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1
Jun 20, 2026Form 4Humes JenniferChief Accounting OfficerTax withholding · $113K · 3,582 sh
Jun 20, 2026Form 4Pulik RichardCFOTax withholding · $67K · 2,129 sh
May 22, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1
May 22, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1
May 20, 2026Form 4Venker EricPresident & Immunovant CEOTax withholding · $1.1M · 34,483 sh · 10b5-1
May 20, 2026Form 4Pulik RichardCFOTax withholding · $615K · 18,962 sh
Apr 20, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1
Apr 20, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1
Apr 20, 2026Form 4Pulik RichardCFOAward · Stock Option (Right to Buy) · $0 · 84,026 sh
Apr 20, 2026Form 4Pulik RichardCFOAward · $0 · 60,644 sh
Apr 20, 2026Form 4Humes JenniferChief Accounting OfficerAward · $0 · 29,173 sh
Apr 20, 2026Form 4Humes JenniferChief Accounting OfficerAward · Stock Option (Right to Buy) · $0 · 27,157 sh
Apr 17, 2026Form 4Oren IlanDirectorTax withholding · $2,834 · 95 sh
Apr 17, 2026Form 4MOMTAZEE JAMES CDirectorTax withholding · $2,804 · 94 sh
Apr 17, 2026Form 4Oren IlanDirectorAward · $0 · 896 sh
Apr 17, 2026Form 4Epperly Melissa B,DirectorAward · $0 · 670 sh
Apr 17, 2026Form 4MOMTAZEE JAMES CDirectorAward · $0 · 469 sh
Mar 31, 2026Form 4Gline MatthewCEO · DirectorTax withholding · $8.4M · 304,684 sh
Mar 31, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorTax withholding · $5.2M · 187,512 sh
Mar 31, 2026Form 4Torti FrankPresident and Vant ChairTax withholding · $4.4M · 160,035 sh
Mar 30, 2026Form 4Gline MatthewCEO · DirectorExercise or conversion · $25.0M · 2,178,150 sh
Mar 30, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $15.0M · 1,306,889 sh
Mar 30, 2026Form 4Gline MatthewCEO · DirectorTax withholding · $1.4M · 53,826 sh
Mar 30, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorTax withholding · $787K · 29,809 sh
Mar 30, 2026Form 4Gline MatthewCEO · DirectorExercise or conversion · — · 97,319 sh
Mar 30, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · — · 58,391 sh
Mar 26, 2026Form 4Fitzgerald MeghanDirectorExercise or conversion · $616K · 70,000 sh
Mar 26, 2026Form 4Fitzgerald MeghanDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 70,000 sh
Mar 20, 2026Form 4Humes JenniferChief Accounting OfficerTax withholding · $402K · 14,526 sh
Mar 20, 2026Form 4Pulik RichardCFOTax withholding · $43K · 1,546 sh
Mar 17, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1
Mar 17, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1
Feb 23, 2026Form 4Torti FrankPresident and Vant ChairExercise or conversion · $2.3M · 587,390 sh · 10b5-1
Feb 23, 2026Form 4Torti FrankPresident and Vant ChairExercise or conversion · Stock Option (Right to Buy) · $0 · 587,390 sh · 10b5-1
Feb 20, 2026Form 4Torti FrankPresident and Vant ChairExercise or conversion · $3.9M · 1,012,610 sh · 10b5-1
Feb 20, 2026Form 4Venker EricPresident & Immunovant CEOTax withholding · $191K · 7,051 sh
Feb 20, 2026Form 4Pulik RichardCFOTax withholding · $27K · 1,000 sh
Feb 20, 2026Form 4Torti FrankPresident and Vant ChairExercise or conversion · Stock Option (Right to Buy) · $0 · 1,012,610 sh · 10b5-1
Feb 19, 2026Form 4Torti FrankPresident and Vant ChairExercise or conversion · $5.4M · 1,400,000 sh · 10b5-1
Feb 19, 2026Form 4Torti FrankPresident and Vant ChairExercise or conversion · Stock Option (Right to Buy) · $0 · 1,400,000 sh · 10b5-1
Feb 13, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1
Feb 13, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1
Feb 9, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $8.3M · 651,558 sh
Feb 9, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorOther · $8.3M · 312,117 sh
Feb 9, 2026Form 4Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 651,558 sh
Jan 20, 2026Form 4Oren IlanDirectorTax withholding · $2,850 · 124 sh
Jan 20, 2026Form 4MOMTAZEE JAMES CDirectorTax withholding · $2,804 · 122 sh
Jan 20, 2026Form 4Epperly Melissa B,DirectorTax withholding · $1,241 · 54 sh
Jan 20, 2026Form 4Oren IlanDirectorAward · $0 · 1,164 sh
Jan 20, 2026Form 4Epperly Melissa B,DirectorAward · $0 · 815 sh
Jan 20, 2026Form 4MOMTAZEE JAMES CDirectorAward · $0 · 609 sh
Jan 12, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1
Jan 12, 2026Form 4Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.

2026 · 20 filings
FiledWhat it is
Nov 9, 202610-QQuarterly report, Q2 2026 — revenue $35.1M (+2136% y/y), net income −$191.6M, EPS −$0.27
Nov 9, 20268-KEarnings release — EPS −$0.30 vs −$0.52 est. (+42.3%); revenue $35.1M (+2136% y/y) 4.6%
Oct 21, 20268-KRoivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)Regulation FD disclosure
Sep 18, 20268-KShareholder vote results
Sep 8, 20268-KRoivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier StudyRegulation FD disclosure
Aug 28, 20268-KOther events
Aug 27, 20268-KRoivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.Regulation FD disclosure
Aug 6, 202610-QQuarterly report, Q1 2026 — revenue $1.4M (−34% y/y), net income −$189.8M, EPS −$0.26
Aug 6, 20268-KEarnings release — EPS −$0.45 vs −$0.45 est. (+0.0%); revenue $1.4M (−34% y/y) 1.5%
Jul 29, 2026ARSAnnual report to shareholders
Jul 29, 2026DEFA14AAdditional proxy materials
Jul 29, 2026DEF 14AProxy statement
May 20, 202610-KAnnual report, FY2025 — revenue $8.3M (−72% y/y), net income −$299.8M, EPS −$0.54
May 20, 20268-KEarnings release — EPS −$0.46 vs −$0.38 est. (−21.1%); revenue $2.5M (−67% y/y) 14.9%
Apr 2, 20268-KRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Results of operations; Regulation FD disclosure
Mar 23, 20268-K/AMaterial definitive agreement
Mar 3, 20268-KRoivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With ModernaMaterial definitive agreement; Regulation FD disclosure; Other events
Mar 3, 20268-KRegulation FD disclosure
Feb 6, 202610-QQuarterly report, Q3 2025 — revenue $2.0M (−78% y/y), net income −$265.9M, EPS −$0.38
Feb 6, 20268-KEarnings release — EPS −$0.36 vs −$0.39 est. (+7.7%); revenue $2.0M (−78% y/y) 22.1%
2025 · 20 filings
FiledWhat it is
Dec 11, 20258-KRoivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor DayRegulation FD disclosure
Nov 10, 202510-QQuarterly report, Q2 2025 — revenue $1.6M (−65% y/y), net income −$113.5M, EPS −$0.17
Nov 10, 20258-KEarnings release — EPS −$0.40 vs −$0.34 est. (−17.6%); revenue $1.6M (−65% y/y) 2.7%
Sep 17, 20258-KRegulation FD disclosure; Other events
Sep 11, 20258-KShareholder vote results
Sep 3, 20258-KRegulation FD disclosure; Other events
Aug 11, 202510-QQuarterly report, Q1 2025 — revenue $2.2M (−73% y/y), net income −$223.4M, EPS −$0.33
Aug 11, 20258-KEarnings release — EPS −$0.30 vs −$0.31 est. (+3.2%); revenue $2.2M (−73% y/y) 2.8%
Jul 29, 2025ARSAnnual report to shareholders
Jul 29, 2025DEF 14AProxy statement
Jul 29, 2025DEFA14AAdditional proxy materials
Jun 25, 20258-KOther events
May 29, 202510-KAnnual report, FY2024 — revenue $29.1M (−11% y/y), net income −$172.0M, EPS −$0.24
May 29, 20258-KEarnings release — EPS −$0.31 vs −$0.23 est. (−34.8%); revenue $7.6M (−16% y/y) 6.4%
Apr 21, 20258-KRegulation FD disclosure
Mar 20, 20258-KDirectors or officers; compensation
Mar 19, 20258-KRegulation FD disclosure; Other events
Feb 21, 20258-KDirectors or officers; compensation
Feb 10, 202510-QQuarterly report, Q3 2024 — revenue $9.0M (−42% y/y), net income $169.4M, EPS $0.23
Feb 10, 20258-KEarnings release — EPS −$0.20 vs −$0.30 est. (+33.3%); revenue $9.0M (−42% y/y) 0.9%
2024 · 20 filings
FiledWhat it is
Dec 3, 20248-KRegulation FD disclosure
Nov 12, 202410-QQuarterly report, Q2 2024 — revenue $4.5M (+23% y/y), net income −$230.2M, EPS −$0.31
Nov 12, 20248-KEarnings release — EPS −$0.37 vs −$0.27 est. (−37.0%); revenue $4.5M (+23% y/y)
Oct 28, 20248-KTermination of a material agreement; Regulation FD disclosure
Sep 23, 20248-KMaterial definitive agreement
Sep 18, 20248-KRegulation FD disclosure
Sep 16, 20248-KShareholder vote results
Sep 10, 20248-KRegulation FD disclosure
Sep 9, 20248-KRegulation FD disclosure
Aug 9, 202410-QQuarterly report, Q1 2024 — revenue $8.0M (−63% y/y), net income $95.3M, EPS $0.12
Aug 8, 20248-KEarnings release — EPS −$0.24 vs −$0.27 est. (+11.1%); revenue $8.0M (−63% y/y) 6.7%
Jul 26, 2024ARSAnnual report to shareholders
Jul 26, 2024DEFA14AAdditional proxy materials
Jul 26, 2024DEF 14AProxy statement
May 30, 202410-KAnnual report, FY2023 — revenue $32.7M (+4% y/y), net income $4.35B, EPS $5.23
May 30, 20248-KMaterial definitive agreement
May 30, 20248-KEarnings release — EPS −$0.28 vs −$0.31 est. (+9.7%); revenue $9.0M (−67% y/y) 3.2%
Apr 2, 20248-KOther events
Feb 13, 202410-QQuarterly report, Q3 2023 — revenue $15.6M (−9% y/y), net income $5.10B, EPS $6.03
Feb 13, 20248-KEarnings release — EPS −$0.26 vs −$0.33 est. (+21.2%); revenue $15.6M (−9% y/y) 0.6%
2023 · 34 filings — 25 × 8-K, 3 × 10-Q, 2 × 8-K/A and 4 other forms
FiledWhat it is
Nov 13, 202310-QQuarterly report, Q2 2023 — revenue $3.6M (−71% y/y), net income −$304.3M, EPS −$0.40
Aug 14, 202310-QQuarterly report, Q1 2023 — revenue $21.6M (+401% y/y), net income −$291.8M, EPS −$0.38
Aug 7, 2023ARSAnnual report to shareholders
Jul 31, 2023DEFA14AAdditional proxy materials
Jul 31, 2023DEF 14AProxy statement
Jun 28, 202310-KAnnual report, FY2022 — revenue $31.5M (−43% y/y), net income −$1.01B, EPS −$1.42
Feb 13, 202310-QQuarterly report, Q3 2022 — revenue $17.1M (−30% y/y), net income −$352.0M, EPS −$0.49

27 current reports (8-K) not listed; the year is on EDGAR.

2022 · 19 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Nov 14, 202210-QQuarterly report, Q2 2022 — revenue $12.5M (−10% y/y), net income −$291.6M, EPS −$0.42
Aug 15, 202210-QQuarterly report, Q1 2022 — revenue $4.3M (−44% y/y), net income −$331.8M, EPS −$0.48
Jul 26, 2022DEFA14AAdditional proxy materials
Jul 26, 2022DEF 14AProxy statement
Jun 28, 202210-KAnnual report, FY2021 — revenue $55.3M (+132% y/y), net income −$845.3M, EPS −$1.26
Feb 14, 202210-QQuarterly report, Q3 2021 — revenue $24.3M, net income −$284.5M, EPS −$0.41

13 current reports (8-K) not listed; the year is on EDGAR.

2021 · 6 filings — 4 × 8-K, 2 × 10-Q
FiledWhat it is
Nov 15, 202110-QQuarterly report, Q2 2021 — revenue $14.0M, net income −$208.5M, EPS −$0.32
Sep 21, 202110-QQuarterly report, Q1 2021 — revenue $7.7M, net income −$82.2M, EPS −$0.13

4 current reports (8-K) not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 144 filings — 86 × 4, 39 × 144, 11 × SCHEDULE 13G/A and 3 other forms
FiledWhat it is
Nov 13, 2026144/ANotice of proposed sale (Form 144), amended
Nov 13, 2026144/ANotice of proposed sale (Form 144), amended
Nov 12, 20264Insider transaction (Form 4)
Nov 12, 20264Insider transaction (Form 4)
Nov 12, 20264Insider transaction (Form 4)
Nov 12, 20264Insider transaction (Form 4)
Nov 12, 20264Insider transaction (Form 4)
Nov 12, 2026144Notice of proposed sale (Form 144)
Nov 10, 2026144/ANotice of proposed sale (Form 144), amended
Nov 10, 2026144/ANotice of proposed sale (Form 144), amended
Nov 10, 2026144/ANotice of proposed sale (Form 144), amended
Nov 10, 2026144Notice of proposed sale (Form 144)
Nov 10, 2026144Notice of proposed sale (Form 144)
Nov 10, 2026144Notice of proposed sale (Form 144)
Nov 10, 2026144Notice of proposed sale (Form 144)
Nov 10, 2026144Notice of proposed sale (Form 144)
Nov 5, 20264Insider transaction (Form 4)
Nov 5, 2026SCHEDULE 13G/AOther filings
Nov 3, 2026144Notice of proposed sale (Form 144)
Oct 30, 20264Insider transaction (Form 4)
Oct 28, 2026144Notice of proposed sale (Form 144)
Oct 27, 20264Insider transaction (Form 4)
Oct 27, 20264Insider transaction (Form 4)
Oct 27, 20264Insider transaction (Form 4)
Oct 27, 2026SCHEDULE 13G/AOther filings

The newest 25 of 144 shown; the full year is on EDGAR.

2025 · 151 filings — 88 × 4, 42 × 144, 10 × SCHEDULE 13G/A and 5 other forms
FiledWhat it is
Dec 31, 20254Insider transaction (Form 4)
Dec 31, 2025144Notice of proposed sale (Form 144)
Dec 29, 20254Insider transaction (Form 4)
Dec 29, 20254Insider transaction (Form 4)
Dec 29, 20254Insider transaction (Form 4)
Dec 29, 2025144Notice of proposed sale (Form 144)
Dec 29, 2025144Notice of proposed sale (Form 144)
Dec 29, 2025144Notice of proposed sale (Form 144)
Dec 23, 20254Insider transaction (Form 4)
Dec 23, 2025144Notice of proposed sale (Form 144)
Dec 23, 2025144Notice of proposed sale (Form 144)
Dec 23, 2025144Notice of proposed sale (Form 144)
Dec 19, 20254Insider transaction (Form 4)
Dec 18, 20254Insider transaction (Form 4)
Dec 18, 20254Insider transaction (Form 4)
Dec 18, 20254Insider transaction (Form 4)
Dec 17, 20254Insider transaction (Form 4)
Dec 17, 2025144Notice of proposed sale (Form 144)
Dec 15, 20254Insider transaction (Form 4)
Dec 15, 2025144/ANotice of proposed sale (Form 144), amended
Dec 15, 2025144Notice of proposed sale (Form 144)
Dec 12, 2025SCHEDULE 13D/AOther filings
Dec 12, 20254Insider transaction (Form 4)
Dec 11, 20254Insider transaction (Form 4)
Dec 9, 2025144Notice of proposed sale (Form 144)

The newest 25 of 151 shown; the full year is on EDGAR.

2024 · 135 filings — 96 × 4, 22 × 144, 12 × SC 13G/A and 3 other forms
FiledWhat it is
Dec 31, 20244Insider transaction (Form 4)
Dec 31, 20244Insider transaction (Form 4)
Dec 27, 2024144Notice of proposed sale (Form 144)
Dec 26, 20244Insider transaction (Form 4)
Dec 26, 20244Insider transaction (Form 4)
Dec 26, 20244Insider transaction (Form 4)
Dec 26, 20244Insider transaction (Form 4)
Dec 26, 20244Insider transaction (Form 4)
Dec 26, 2024144Notice of proposed sale (Form 144)
Dec 26, 2024144Notice of proposed sale (Form 144)
Dec 23, 2024144Notice of proposed sale (Form 144)
Dec 20, 20244Insider transaction (Form 4)
Dec 20, 2024144Notice of proposed sale (Form 144)
Dec 18, 2024144Notice of proposed sale (Form 144)
Dec 5, 20244Insider transaction (Form 4)
Dec 2, 20244Insider transaction (Form 4)
Nov 22, 20244Insider transaction (Form 4)
Nov 22, 20244Insider transaction (Form 4)
Nov 22, 20244Insider transaction (Form 4)
Nov 20, 2024144Notice of proposed sale (Form 144)
Nov 14, 2024SC 13G/APassive holder above 5% (Schedule 13G), amended
Nov 12, 2024SC 13G/APassive holder above 5% (Schedule 13G), amended
Nov 12, 2024SC 13GPassive holder above 5% (Schedule 13G)
Nov 8, 2024SC 13GPassive holder above 5% (Schedule 13G)
Nov 4, 2024SC 13G/APassive holder above 5% (Schedule 13G), amended

The newest 25 of 135 shown; the full year is on EDGAR.

2023 · 223 filings — 119 × 4, 84 × 144, 6 × SC 13G/A and 10 other forms

Counted, not listed; the year is on EDGAR.

2022 · 109 filings — 60 × 4, 17 × 424B3, 7 × EFFECT and 11 other forms

Counted, not listed; the year is on EDGAR.

2021 · 64 filings — 20 × 3, 9 × 425, 6 × CORRESP and 13 other forms

Counted, not listed; the year is on EDGAR.

2020 · 10 filings — 5 × 4, 5 × SC 13D/A

Counted, not listed; the year is on EDGAR.

2019 · 35 filings — 17 × 4, 14 × SC 13D/A, 2 × SC 13D and 2 other forms

Counted, not listed; the year is on EDGAR.

2018 · 14 filings — 6 × SC 13D/A, 5 × 4, 2 × SC 13D and 1 other form

Counted, not listed; the year is on EDGAR.

2017 · 4 filings — 2 × SC 13D/A, 1 × 4, 1 × SC 13G

Counted, not listed; the year is on EDGAR.

2016 · 3 filings — 1 × 3, 1 × SC 13D/A, 1 × SC 13G

Counted, not listed; the year is on EDGAR.

2015 · 4 filings — 2 × 3, 1 × SC 13D, 1 × SC 13D/A

Counted, not listed; the year is on EDGAR.

About this data#

Roivant Sciences Ltd. (ROIV) has 1,015 filings on EDGAR going back to 2015: 5 annual reports, 17 quarterly reports and 83 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on May 20, 2026 for the fiscal year ended Mar 31, 2026. The most recent 8-K, on Nov 9, 2026, furnished a press release headed “Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update”. Over the last 13 months insiders sold $526.6M in 55 sales and bought nothing on the open market; 138 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Roivant Sciences Ltd., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read ROIV's latest 10-K?
ROIV's latest annual report, a 10-K, was filed on May 20, 2026 for the fiscal year ended Mar 31, 2026. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did ROIV last file an 8-K?
On Nov 9, 2026 it furnished a press release headed “Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Nov 9, 2026.
Are ROIV insiders buying or selling?
Over the last 13 months insiders sold $526.6M in 55 sales and bought nothing on the open market; 138 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Pulik Richard (CFO) sold 175,000 shares on Nov 11, 2026 for $7.3M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has ROIV made?
1,015 filings are on EDGAR under the registrant records that have been Roivant Sciences Ltd., going back to 2015; 708 of them are insider ownership forms (Forms 3, 4, 5 and 144).